Matrix metalloprotease 9 and remodeling after myocardial infarction
Abstract
The objective of the work was to study the distribution of metalloprotease 9 (MMP9) in tissues after myocardial infarction. We studied anatomopathological material from 30 patients, the primary victims of acute transmural myocardial infarction. Average age - 63,7 years. There were 18 men and 12 women. 16 patients died in the period up to 3 days, 14 patients - in a period from 3 days to 1 month. Samples were fixed in formalin and immunohistochemical staining for MMP9 was conducted. We used rabbit IgG monoclonal antibody to MMP9 (Epitomics, Clone 1D: EP1254, Cat. N 2551-1, Lot YG 113001P) in the working dilution of 1: 100 - 1: 250. At fatal outcomes that happened within a few hours after the onset of a heart attack a large number of MMP9 was detected in neutrophils in the blood vessels at near infarction zone. In the period from 1 to 2 hours MMP9 was detected in the extracellular matrix in the area of infarction. In the period from 3 to 30 days MMP9 was detected only in fibroclasts at forming cardiosclerosis zone. Thus, the use of staining for MMP9 is convenient for determination of the time elapsed after myocardial infarction in post mortem examination.
About the Authors
M. G. Shurygin
ФГБУ «Научный центр реконструктивной и восстановительной хирургии» СО РАМН; ФГБУН Иркутский научный центр СО РАН
Russian Federation
Russian Federation
I. A. Shurygina
ФГБУ «Научный центр реконструктивной и восстановительной хирургии» СО РАМН; ФГБУН Иркутский научный центр СО РАН
Russian Federation
Russian Federation
N. N. Dremina
ФГБУ «Научный центр реконструктивной и восстановительной хирургии» СО РАМН
Russian Federation
Russian Federation
O. V. Kanya
ФГБУ «Научный центр реконструктивной и восстановительной хирургии» СО РАМН
Russian Federation
Russian Federation
References
1. Меркулов Г.А Курс патогистологической техники. - Л.: Медицина, 1969. - С. 13-15, 52 - 59.
2. Соловьева Н.И. Матриксные металлопротеиназы и их биологические функции // Ж. биоорганич. химии. - 1998. - Т. 24. - С. 217 - 226.
3. Соловьева Н.И. Матриксные металлопротеиназы: регуляция активности и роль в процессе онкогенеза // Вопр. мед. химии. - 2000. - № 5. -С. 30-31.
4. Bergers, G., Javaherian K., Lo K.M., Folkman J. et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice // Science. - 1999. -N 284 (5415). - P. 808 - 812.
5. Bode W., Fernandez-Catalan С., Tschesche H. et al. Structural properties of matrix metalloproteinases // Cell. Mol. Life Sci. - 1999. - Vol. 55. - P. 639 - 652.
6. Close D.R. Matrix metalloproteinase inhibitors in rheumatic diseases // Ann. Rheum. Dis. - 2001. -Vol. 60, N 3. - P. 62 - 67.
7. Galis Z.S., Sukhova G.K., Lark M.W. Increased expression of matrix metalloproteinase and matrix degrading activity in vulnerable regions of human atherosclerotic plaques // J. Clin. Invest. - 1994. -Vol. 94, N 6. - P. 2493 - 2503.
8. Hidalgo М., Eckhardt G.S. Development of matrix metalloproteinase inhibitors in cancer therapy // J. Nation. Cancer Inst. - 2001. - Vol. 93, N 3. -P. 178 - 193.
9. Hoekstra R., Eskens F.A.L.M., Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives // The Oncologist. - 2001. -Vol. 6, N 5. - P. 415 - 427.
10. Jefferis B.J., Whincup P., Welsh P. et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women // Atherosclerosis. - 2010. - Vol. 208, N 2. - P. 557 - 563.
11. Kelly D., Cockerill G., Ng L.L., Thompson M. et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort stud // Eur. Heart. J. - 2007. - Vol. 28. - P. 711-718.
12. Kim H.E., Dalal S.S., Young E. et al. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction // J. Clin. Invest. - 2000. - Vol. 106. -P. 857 - 866.
13. Lehrke M., Greif M., Broedl U.C. et al. MMP-1 serum levels predict coronary atherosclerosis in humans // Cardiovasc. Diabetol. - 2009. - Vol. 8. -P. 50 - 58.
14. Liotta L.A., Steeg P.S. Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation // Cell. - 1991. -Vol. 64, N 2. - P. 327 - 336.
15. Loftus I.M., Naylor A.R., Goodall S. et al. Increased matrix MMP9 activity in unstable carotid plaques: а potential role in acute plaque disruption // Stroke. - 2000. - Vol. 31, N 1. - P. 40 - 47.
16. Matrisian L.M., Cancer biology: extracellular proteinases in malignancy // Curr. Biol. - 1999. -Vol. 9, N 20. - P. R776 - R778.
17. Mohammed F.F., Smookler D.S. Metalloproteinases, inflammation, and rheumatoid arthritis // Ann. Rheum. Dis. - 2003. - Vol. 62, N 2. - P. 1143-1147.
18. Nagase H., Woessner J.F. Matrix Metalloproteinases // J. Biol. Chem. - 1999. -Vol. 274, N 31. - P. 21491 -21494.
19. Rudek M.A., Figg W.D., Dyer V. et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer // J. Clin. Oncol. - 2001. - Vol. 19, N 2. -P. 584 - 592.
20. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior // Апп. Rev. Cell. Dev. Biol. - 2001. - Vol. 17. - P. 463 - 516.
21. Troeberg L., Nagase H. Analysis of TIMP expression and activity // Methods Mol. Med. - 2007. -Vol. 135. - P. 251-267.
22. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M. et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9) // Critical. Rev. Biochem. Mol. Biol. - 2002. - Vol. 37, N 6. - P. 375 - 536.
23. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling // FASEB J. - 1991. - Vol. 5, N 8. - P. 2145 - 2154.
Review
For citations:
Shurygin M.G., Shurygina I.A., Dremina N.N., Kanya O.V. Matrix metalloprotease 9 and remodeling after myocardial infarction. Acta Biomedica Scientifica. 2013;(2(1)):138-141. (In Russ.)
Views:
563
.png)
Email this article 
